Hoekstra Eva M, Liem Sophie Ie, Ahmed Saad, Levarht Nivine, Fehres Cynthia M, Giuca Adrian, Ajmone Marsan Nina, Huizinga Tom Wj, de Vries-Bouwstra Jeska K
Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands.
Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands.
J Scleroderma Relat Disord. 2024 Oct;9(3):185-191. doi: 10.1177/23971983241255550. Epub 2024 Jun 3.
Troponin I has been suggested as a more specific diagnostic biomarker for myocardial involvement in systemic sclerosis than the frequently used troponin T. The aim of this study is to evaluate the additive value of troponin I to detect myocardial involvement in systemic sclerosis. To this end, we evaluated the association between troponin I levels and myocardial involvement in systemic sclerosis patients.
A cross-sectional observational study was performed, including 20 healthy controls and four groups of each 20 systemic sclerosis patients from the Leiden Combined Care in Systemic Sclerosis cohort: (1) patients with myocardial involvement, (2) patients with myositis, (3) patients with elevated troponin T and creatine kinase levels but without organ involvement, and (4) patients without any signs of organ involvement. Troponin I levels were measured using enzyme-linked immunosorbent assay. Troponin I levels were compared between the different groups using the Mann-Whitney and Kruskal-Wallis tests.
The mean age of the 80 included patients was 56 years; 61% of the study population was female. Troponin I levels were not significantly different between patients with and without myocardial involvement (2.7 (0.5-15.3) vs 1.2 (0.1-6.6) ng/L; p = 0.117). Systemic sclerosis patients were more often positive for troponin I than healthy controls (70.0% vs 30.0%; p = 0.001).
Elevated troponin I was not of additional value to diagnose myocardial involvement in systemic sclerosis patients.
与常用的肌钙蛋白T相比，肌钙蛋白I被认为是系统性硬化症中心肌受累更具特异性的诊断生物标志物。本研究的目的是评估肌钙蛋白I在检测系统性硬化症心肌受累方面的附加价值。为此，我们评估了系统性硬化症患者肌钙蛋白I水平与心肌受累之间的关联。
进行了一项横断面观察性研究，纳入20名健康对照者以及来自莱顿系统性硬化症联合护理队列的四组系统性硬化症患者，每组20例：（1）心肌受累患者；（2）肌炎患者；（3）肌钙蛋白T和肌酸激酶水平升高但无器官受累的患者；（4）无任何器官受累迹象的患者。采用酶联免疫吸附测定法测量肌钙蛋白I水平。使用Mann-Whitney检验和Kruskal-Wallis检验比较不同组之间的肌钙蛋白I水平。
纳入的80例患者的平均年龄为56岁；研究人群中61%为女性。有心肌受累和无心肌受累的患者之间肌钙蛋白I水平无显著差异（2.7（0.5 - 15.3）对1.2（0.1 - 6.6）ng/L；p = 0.117）。系统性硬化症患者肌钙蛋白I阳性的比例高于健康对照者（70.0%对30.0%；p = 0.001）。
肌钙蛋白I升高对诊断系统性硬化症患者的心肌受累并无附加价值。
